P&G To Develop Phase II GERD Drug Under Agreement With ARYx Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
P&G will make a $25 mil. up-front payment to ARYx Therapeutics to develop and commercialize the serotonin type 4 agonist.
You may also be interested in...
Aryx’s Constipation Drug Boosts Bowel Function
Despite good results, GI agent takes back seat to firm’s promising late-stage heart drugs.
Aryx’s Constipation Drug Boosts Bowel Function
Despite good results, GI agent takes back seat to firm’s promising late-stage heart drugs.
Vernakalant, Cardiome Limelight Could Make ARYx Glow
Amiodarone-derived, Phase II atrial fibrillation drug might prove even better, ARYx tells “The Pink Sheet” DAILY.